List view / Grid view
10 February 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announce the publication of their AVERROES study of apixaban in The New England Journal of Medicine...
10 February 2011 | By The Scott Partnership
Novozymes Biopharma's recombinant human albumin, albucult, will be used by Neomend...
10 February 2011 | By The Scott Partnership
It reveals trends in the design of post-approval research & identifies best practices in observational studies & patient registries...
10 February 2011 | By Eli Lilly and Company
A new approach to research, along with public policies that support medical innovation, will help biopharmaceutical companies address stubborn diseases...
10 February 2011 | By Novartis
Patients with COPD treated with Onbrez® Breezhaler® & tiotropium notice improvements...
9 February 2011 | By Novartis
NEJM published a study that shows Afinitor® tablets plus BSC more than doubled PFS...
9 February 2011 | By IDEA Pharma
IDEA Pharma is delighted to announce the recent appointment of Michael Morgan-Curran to its ever-increasing ranks...
9 February 2011 | By Boehringer Ingelheim
Announcement covers global technical development and manufacturing for antibody-based therapeutics...
8 February 2011 | By Dahlgren Communications
Hamilton introduces the TADM 96 Multi-Channel Pipetting Head, with aspiration & dispense monitoring technology in every channel...
8 February 2011 | By The Scott Partnership
Molecular Profiles, continues expansion of its manufacturing capabilities with the recent purchase of the Xcelodose 120S system...
8 February 2011 | By Premier Research Group Limited
Premier Research Group Ltd, announces the appointment of Sue Robinson to the position of Director of Patient Recruitment...
8 February 2011 | By Johnson & Johnson
Johnson & Johnson and Crucell N.V. provide further information regarding Johnson & Johnson's proposed acquisition of Crucell...
8 February 2011 | By Kapler Communications
New white paper from Malvern examines benefits of real-time analysis for process development...
7 February 2011 | By AstraZeneca
AstraZeneca today announced that the phase III ENTHUSE Study 15...
7 February 2011 | By AstraZeneca
This study is in addition to the companies’ Phase III RENAISSANCE programme for TC-5214...
